Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Systemic treatment options for untreated patients with metastatic clear cell renal cancer.

Molina AM, Motzer RJ, Heng DY.

Semin Oncol. 2013 Aug;40(4):436-43. doi: 10.1053/j.seminoncol.2013.05.013. Review.

PMID:
23972707
2.

Targeted Therapy for Metastatic Renal Cell Carcinoma.

Afriansyah A, Hamid AR, Mochtar CA, Umbas R.

Acta Med Indones. 2016 Oct;48(4):335-347. Review.

3.

Signaling inhibitors in metastatic renal cell carcinoma.

Escudier B.

Cancer J. 2008 Sep-Oct;14(5):325-9. doi: 10.1097/PPO.0b013e3181867605.

PMID:
18836338
4.

A "game of thrones" in metastatic renal cell carcinoma: vascular endothelial growth factor-tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors battling for position.

Pal SK, Vogelzang NJ.

Clin Genitourin Cancer. 2013 Mar;11(1):1-4. doi: 10.1016/j.clgc.2012.11.006. Epub 2012 Dec 29. No abstract available.

5.

[Novelties in the treatment for advanced renal-cell cancer].

Maráz A.

Orv Hetil. 2011 Apr 24;152(17):655-62. doi: 10.1556/OH.2011.29100. Review. Hungarian.

PMID:
21464023
6.

Targeted therapies in metastatic renal cancer in 2009.

Bastien L, Culine S, Paule B, Ledbai S, Patard JJ, de la Taille A.

BJU Int. 2009 May;103(10):1334-42. doi: 10.1111/j.1464-410X.2009.08454.x. Epub 2009 Mar 11. Review.

7.

Pazopanib as second-line treatment after sunitinib or bevacizumab in patients with advanced renal cell carcinoma: a Sarah Cannon Oncology Research Consortium Phase II Trial.

Hainsworth JD, Rubin MS, Arrowsmith ER, Khatcheressian J, Crane EJ, Franco LA.

Clin Genitourin Cancer. 2013 Sep;11(3):270-5. doi: 10.1016/j.clgc.2013.04.006. Epub 2013 May 9.

PMID:
23665131
8.

Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy.

Calvo E, Schmidinger M, Heng DY, Grünwald V, Escudier B.

Cancer Treat Rev. 2016 Nov;50:109-117. doi: 10.1016/j.ctrv.2016.09.002. Epub 2016 Sep 10. Review.

PMID:
27664394
9.

Sarcomatoid dedifferentiation in metastatic clear cell renal cell carcinoma and outcome on treatment with anti-vascular endothelial growth factor receptor tyrosine kinase inhibitors: a retrospective analysis.

Beuselinck B, Lerut E, Wolter P, Dumez H, Berkers J, Van Poppel H, Joniau S, Oyen R, De Wever L, Strijbos M, Paridaens R, Schöffski P.

Clin Genitourin Cancer. 2014 Oct;12(5):e205-14. doi: 10.1016/j.clgc.2014.04.004. Epub 2014 May 9.

PMID:
24861951
10.

New treatment approaches in metastatic renal cell carcinoma.

Mancuso A, Sternberg CN.

Curr Opin Urol. 2006 Sep;16(5):337-41. Review.

PMID:
16905978
11.

Systemic therapy for metastatic non-clear-cell renal cell carcinoma: recent progress and future directions.

Chowdhury S, Matrana MR, Tsang C, Atkinson B, Choueiri TK, Tannir NM.

Hematol Oncol Clin North Am. 2011 Aug;25(4):853-69. doi: 10.1016/j.hoc.2011.05.003. Review.

12.

Sequential targeted therapy after pazopanib therapy in patients with metastatic renal cell cancer: efficacy and toxicity.

Bellmunt J, Pons F, Foreshew A, Fay AP, Powles T, Porta C, Bracarda S, Lampron ME, Cerbone L, Sternberg CN, Hutson TE, Choueiri TK.

Clin Genitourin Cancer. 2014 Aug;12(4):262-9. doi: 10.1016/j.clgc.2014.03.002. Epub 2014 Mar 14.

PMID:
24795159
13.

Treatment patterns: targeted therapies indicated for first-line management of metastatic renal cell carcinoma in a real-world setting.

Hess G, Borker R, Fonseca E.

Clin Genitourin Cancer. 2013 Jun;11(2):161-7. doi: 10.1016/j.clgc.2012.10.003. Epub 2012 Dec 23.

PMID:
23267717
14.

Tolerability of first-line therapy for metastatic renal cell carcinoma.

Porta C, Szczylik C.

Cancer Treat Rev. 2009 May;35(3):297-307. doi: 10.1016/j.ctrv.2008.12.003. Epub 2009 Feb 26. Review.

PMID:
19249157
15.

[Medical treatment of renal cell carcinoma].

Guy L, Bay JO, Bastide C, Mahammedi H, Bruyere F, Karsenty G.

Prog Urol. 2013 Nov;23(15):1225-37. doi: 10.1016/j.purol.2013.09.011. Epub 2013 Oct 21. Review. French.

PMID:
24183081
16.

[Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].

Miller K, Bergmann L, Gschwend J, Keilholz U.

Aktuelle Urol. 2011 Jul;42(4):242-6. doi: 10.1055/s-0031-1271548. Epub 2011 Jun 30. German.

PMID:
21720974
17.

A contemporary update on rates and management of toxicities of targeted therapies for metastatic renal cell carcinoma.

Alasker A, Meskawi M, Sun M, Ismail S, Hanna N, Hansen J, Tian Z, Bianchi M, Perrotte P, Karakiewicz PI.

Cancer Treat Rev. 2013 Jun;39(4):388-401. doi: 10.1016/j.ctrv.2012.12.006. Epub 2013 Jan 12.

PMID:
23317510
18.

Pazopanib outscores sunitinib on tolerability.

[No authors listed]

Cancer Discov. 2014 Jan;4(1):OF8. doi: 10.1158/2159-8290.CD-NB2013-131. Epub 2013 Sep 19.

19.

Management of metastatic renal cell carcinoma progressed after sunitinib or another antiangiogenic treatment.

Iacovelli R, Palazzo A, Trenta P, Mezi S, Pellegrino D, Naso G, Cortesi E.

Am J Clin Oncol. 2014 Dec;37(6):611-5. doi: 10.1097/COC.0b013e31827de888. Review.

PMID:
23388560
20.

Prognostic factors of survival for patients with metastatic renal cell carcinoma with brain metastases treated with targeted therapy: results from the international metastatic renal cell carcinoma database consortium.

Vickers MM, Al-Harbi H, Choueiri TK, Kollmannsberger C, North S, MacKenzie M, Knox JJ, Rini BI, Heng DY.

Clin Genitourin Cancer. 2013 Sep;11(3):311-5. doi: 10.1016/j.clgc.2013.04.012. Epub 2013 May 15.

PMID:
23684422

Supplemental Content

Support Center